Illumina, Inc. today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research ...

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Illumina, Inc. has announced that it is collaborating with the Wellcome Trust Sanger Institute (WTSI) and the Wellcome Trust Case-Control Consortium (WT-CCC) on the design of a custom Sentrix® ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) on October 23 and set a price target of $252.00. The company’s shares closed yesterday at $141. ...

On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. ... Total Microarray revenues were also down by 7.8%, the pandemic being one of the reasons behind it.

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and ...

We offer Illumina microarray processing and expertise accessible to both internal and external researchers. All samples received are stored prior to analysis in a dedicated biobanking facility with 24 ...

Illumina (ILMN) reported $1.08 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1%. EPS of $0.09 for the same period compares to $0.08 a year ago. The ...

Patrick B Donnelly, an analyst from Citi, maintained the Hold rating on Illumina (ILMN – Research Report). The associated price target remains the same with $165.00. Discover outperforming ...

Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.87 per share in its upcoming release, pointing to a year-over-year increase of 163.6%. It is anticipated ...